Sarcopenia
Conditions
Interventions
Trial Group:Peitu Shengji electroacupuncture (acupoints: Jianyu, Zhongli, Wuli of Hand Yangming
Zusanli, Biguang, Xijuyu of Foot Yangming. Needle size: 50mm*0.2mm, inserted straight to obtain Qi, connected to electroacupuncture device with intermittent wave, frequency 4 Hz, current intensity adj
3 times per week on Mondays, Wednesdays, Fridays, each session lasting 20 minutes) combined with basic treatment (exercise training + nutritional support + health education)
Control Group:Sham electroacupuncture at non-acupoints (2cm beside the acupoints used in the trial group, needle size: 25mm*0.2mm, shallow insertion 1-3mm, no manipulation to avoid obtaining Qi
connected to electroacupuncture device with intermittent wave, frequency 4 Hz, current intensity adjusted for patient comfort
Sponsors
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for sarcopenia; patients must simultaneously meet the criteria for low muscle strength and low muscle mass (referencing the Asian Working Group for Sarcopenia (AWGS) 2025 Consensus Update): (1) Low muscle strength (handgrip strength): Aged 50~64 (Male = 65 (Male = 65 (Male < 7.0 kg/m^2, Female < 5.4 kg/m^2). 2. Absence of other cachexia or diseases causing sarcopenia. 3. No gender restriction. 4. Have not received regular treatment for sarcopenia within the past year. 5. Capable of understanding the trial process, rights, and obligations, and willing to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Cognitive dysfunction affecting the understanding of the trial process, rights, and obligations. 2. Severe mental illness, dementia, or other conditions preventing cooperation with the trial. 3. Comorbidities such as disability or severe bone/joint diseases that would affect the progress and results of the trial. 4. Abnormal liver or kidney function (Cr > 82 µmol/L, AST > 35 U/L), as the trial requires observation of serum markers related to liver and kidney function. 5. Currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-meter gait speed; | — |
Secondary
| Measure | Time frame |
|---|---|
| Appendicular Skeletal Muscle Mass (ASM);Calf circumference;Handgrip strength; SPPB functional scale;5-time chair stand test time;C-terminal agrin fragment (CAF);Irisin;Cr/CysC; | — |
Countries
China
Contacts
Public ContactZhang Yun
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital
Outcome results
None listed